NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 161 filers reported holding NEVRO CORP in Q3 2019. The put-call ratio across all filers is 2.90 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $367,000 | -59.2% | 2,630 | -49.4% | 0.00% | -63.6% |
| Q4 2020 | $900,000 | +24.1% | 5,200 | 0.0% | 0.01% | +10.0% |
| Q3 2020 | $725,000 | -77.6% | 5,200 | -80.8% | 0.01% | -77.8% |
| Q2 2020 | $3,238,000 | +16.1% | 27,100 | -2.9% | 0.04% | +2.3% |
| Q1 2020 | $2,790,000 | -11.8% | 27,900 | +4.1% | 0.04% | +37.5% |
| Q4 2019 | $3,163,000 | +35.8% | 26,800 | -1.1% | 0.03% | +28.0% |
| Q3 2019 | $2,330,000 | +32.6% | 27,100 | 0.0% | 0.02% | +31.6% |
| Q2 2019 | $1,757,000 | +3986.0% | 27,100 | +5320.0% | 0.02% | – |
| Q1 2018 | $43,000 | +22.9% | 500 | 0.0% | 0.00% | – |
| Q4 2017 | $35,000 | -22.2% | 500 | 0.0% | 0.00% | – |
| Q3 2017 | $45,000 | +21.6% | 500 | 0.0% | 0.00% | – |
| Q2 2017 | $37,000 | -21.3% | 500 | 0.0% | 0.00% | – |
| Q1 2017 | $47,000 | +4600.0% | 500 | +12400.0% | 0.00% | – |
| Q3 2016 | $1,000 | 0.0% | 4 | 0.0% | 0.00% | – |
| Q2 2016 | $1,000 | – | 4 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadfin Capital, LLC | 622,615 | $38,920,000 | 8.04% |
| Tamarack Advisers, LP | 160,000 | $10,002,000 | 3.97% |
| Birch Run Capital Advisors, LP | 187,425 | $11,716,000 | 3.72% |
| Prosight Management, LP | 128,765 | $8,049,000 | 3.52% |
| Ratan Capital Management LP | 38,653 | $2,416,000 | 3.44% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 579,463 | $36,222,000 | 1.39% |
| Spark Investment Management LLC | 403,400 | $25,216,000 | 1.17% |
| Sivik Global Healthcare LLC | 50,000 | $3,126,000 | 1.15% |
| ArrowMark Colorado Holdings LLC | 1,882,009 | $117,644,000 | 1.11% |
| PFM Health Sciences, LP | 721,229 | $45,084,000 | 1.00% |